Incidence and Risk of Proteinuria with Aflibercept in Cancer Patients: A Meta-Analysis

BACKGROUND: Aflibercept is a human recombinant fusion protein with antiangiogenic effects that functions as a decoy receptor to bind vascular endothelial growth factor A. Proteinuria is one of its major adverse effects with a substantial variation in the incidence rate, and the overall risk of prote...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Ling, Zhao, Qiong, Ye, Xianghua, Zhou, Yun, Hu, Danna, Zheng, Shusen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4218823/
https://www.ncbi.nlm.nih.gov/pubmed/25365378
http://dx.doi.org/10.1371/journal.pone.0111839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4218823/
https://www.ncbi.nlm.nih.gov/pubmed/25365378
http://dx.doi.org/10.1371/journal.pone.0111839

Ejemplares similares